KMT2A重排急性白血病（KMT2A-r-AL）是临床上较为难治的白血病类型，给患者和医生都带来了很大的挑战。异基因造血干细胞移植（allo-HSCT）是目前唯一的治愈手段，然而，影响其长期生存的预后因素却一直未得到明确。在本次会议上，卢岳教授的研究正是围绕这一核心问题展开。

卢岳教授在访谈中提到，KMT2A重排急性白血病的转归依赖于多方因素，尤其是移植前的缓解状态和移植后的早期监测。然而，面对众多的预后因素，如何实施精细化的个体化治疗，成为了各位临床医生的焦点。面对技术发展和治疗策略的不断演变，医院在日常手术及患者管理中，更需要注重精准决策，提高治愈率。

是由 Syndax 制药公司研发的一款口服、首创的 menin 抑制剂，用于治疗 KMT2A 重排（KMT2A r ）的急性白血病、NPM1 突变（NPM1 m ）的急性髓系白血病（AML）以及实体瘤。menin 与 KMT2A 蛋白复合物之间的相互作用会导致基因表达异常，驱动白血病发生相关的转录过程。

急性淋巴细胞白血病（ALL）治疗面临困境，尤其是 KMT2A 重排（KMT2A-R）亚型预后差。研究人员开展 KMT2A-R ALL 靶向治疗研究，发现抑制 DYRK1A 可使癌细胞对 BCL2 抑制敏感，双抑制能减少白血病负担，为高风险 ALL 治疗提供新策略。 白血病是一种严重威胁人类健康的 ...

Data from a phase 1a dose-escalation study of ziftomenib in NPM1-mutated and KMT2A-rearranged AML is due to be presented at this year's ASH congress. Syndax is also preparing to give new data on ...

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

Additionally, multiple trials of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2A-rearranged acute leukemia are ongoing across the treatment landscape, including in ...

which will evaluate ziftomenib in combination with either 7+3 chemotherapy or venetoclax/azacitidine in first-line NPM1-mutated and KMT2A-rearranged AML. This alignment could potentially expedite ...

Overall, surveyed physicians provided high ratings related to Revuforj’s clinical profile in both r/r KMT2A acute leukemias and NPM1 AML. Analyst Anupam Rama writes that surveyed physicians ...